9Bio Therapeutics uses a computationally-guided structural biology platform to design cancer therapeutics that selectively target the unique metabolomic and chemical signatures of the tumor microenvironment. This approach enhances drug efficacy and improves patient safety by minimizing off-tumor toxicity to healthy tissues. The platform enables the development of safer, more efficacious precision oncology treatments, including novel antibody-drug conjugates and protein-based therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
Current immuno-oncology therapeutics often damage healthy tissues due to poor targeting, leading to severe side effects, early treatment discontinuation, and reduced patient survival rates. This lack of specificity limits the effectiveness and tolerability of these treatments.
Solution
9Bio utilizes an AI-guided structural biology platform to design immuno-oncology therapeutics with enhanced specificity for tumors, minimizing damage to healthy tissues. The platform prioritizes the anatomical and biochemical context of proteins, differentiating between normal and cancerous tissue based on the unique signatures of the cancer microenvironment. This approach aims to generate safer and more efficacious therapeutics by focusing on the 'where' of protein behavior, paving the way for novel and highly targeted cancer treatments.
Target Audience
The primary target audience includes biotechnology companies and researchers focused on developing innovative protein-based therapeutics, including antibodies, engineered cytokines, CAR T cells, and ligand/receptor mimetics.
Features
- AI-guided structural biology platform for designing highly specific oncology therapeutics.
- Focus on the anatomical and biochemical context of protein targets within the tumor microenvironment.
- Prioritization of target engagement within tumors to avoid premature clearance and improve bioavailability.
- Capability to explore novel mechanisms of action that may be too toxic in healthy tissues with traditional approaches.
- Pipeline includes a checkpoint inhibitor antibody, an antibody-drug conjugate, and an engineered cytokine.